secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001213900-24-084844
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra resubmits reproxalap NDA for dry eye disease after positive Phase 3 trial
--------------------------------------------------------------------------------

- Resubmission includes positive results from FDA-requested symptom trial.
- Phase 3 dry eye chamber trial met primary endpoint (ocular discomfort, P=0.004).
- If approved, reproxalap would be first chronic dry eye therapy with acute symptom and redness data.
- FDA review expected within 6 months of acceptance; acknowledgment in 30 days.
- Reproxalap showed acute activity in reducing dry eye symptoms and ocular redness in trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024084844/0001213900-24-084844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024084844/ea021662501-8k_aldeyra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-084844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer